<scp>TRE</scp>
            atment of
            <scp>AT</scp>
            opic eczema (
            <scp>TREAT</scp>
            ) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries

Gerbens, L.A.A.; Apfelbacher, Christian; Irvine, Alan D.; Barbarot, S.; Booij, Richard J. de; Boyce, A. J.; Deleuran, M.; Eichenfield, Lawrence F.; Hof, Michel H.; Middelkamp-Hup, M. A.; Roberts, Amanda; Schmitt, Jochen; Vestergaard, Christian; Wall, Dmitri; Weidinger, Stephan; Williamson, Paula; Flohr, Carsten; Spuls, Phyllis I.

doi:10.1111/bjd.16714

Cited by 29 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar developments exist in other research fields [ 44 , 45 , 46 ] and although some recommendations exist for various SB measurement tools and questionnaires [ 22 , 47 ], no other COS exists for device-measured SB to our knowledge. This tool is recommended for use in all studies where change in SB is an outcome.…”

Section: Discussionmentioning

confidence: 57%

A Standardised Core Outcome Set for Measurement and Reporting Sedentary Behaviour Interventional Research: The CROSBI Consensus Study

Curran

Dowd²,

Peiris

et al. 2022

IJERPH

View full text Add to dashboard Cite

Heterogeneity of descriptors and outcomes measured and reported in sedentary behaviour (SB) research hinder the meta-analysis of data and accumulation of evidence. The objective of the Core Research Outcomes for Sedentary Behaviour Interventions (CROSBI) consensus study was to identify and validate, a core outcome set (COS) to report (what, how, when to measure) in interventional sedentary behaviour studies. Outcomes, extracted from a systematic literature review, were categorized into domains and data items (COS v0.0). International experts (n = 5) provided feedback and identified additional items, which were incorporated into COS v0.1. A two round online Delphi survey was conducted to seek consensus from a wider stakeholder group and outcomes that achieved consensus in the second round COS (v0.2), were ratified by the expert panel. The final COS (v1.0) contains 53 data items across 12 domains, relating to demographics, device details, wear-time criteria, wear-time measures, posture-related measures, sedentary breaks, sedentary bouts and physical activity. Notably, results indicate that sedentary behaviour outcomes should be measured by devices that include an inclinometry or postural function. The proposed standardised COS is available openly to enhance the accumulation of pooled evidence in future sedentary behaviour intervention research and practice.

show abstract

Section: Discussionmentioning

confidence: 57%

A Standardised Core Outcome Set for Measurement and Reporting Sedentary Behaviour Interventional Research: The CROSBI Consensus Study

Curran

Dowd²,

Peiris

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Panel participants were selected to provide representation of key stakeholder groups; physicians and specialist nurses with experience in the management of patients with moderate-to-severe AD, and patients/patient association representatives. In keeping with other similar initiatives, panellists were recruited from a wide range of countries and geographical locations ( 3 – 5 , 16 , 17 ). Further details on participant selection are available in Appendix S1 1 .…”

Section: Methodsmentioning

confidence: 99%

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

Bruin‐Weller

Biedermann²,

Bissonnette³

et al. 2021

Acta Derm Venereol

View full text Add to dashboard Cite

Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steerng Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target-orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation.

show abstract

“…Data collection was based on the TREAT core dataset. 15 , 17 , 18 The following baseline characteristics were retrieved: demographics (sex, age, ethnicity, educational status: ISCED [International Standard Classification of Education] classification), health‐related characteristics (disease duration, comorbidities, outpatient daycare treatments, and hospitalizations for AD) and work‐related characteristics (work status: Eurostat classification [e.g., [self‐/un]employed], number of days lost from usual activities [e.g., work, study], problems at work [e.g., fatigue], reasons for not working [e.g., retired]).…”

Section: Methodsmentioning

confidence: 99%

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab

Bosma

Ouwerkerk

Günal

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic dermatological condition that is associated with impairment of quality of life and work productivity. 1 Skin diseases were found the 18th leading cause of global disability-adjusted life years. Excluding mortality, skin diseases were the fourth leading cause of disability worldwide. 2 Of all skin diseases, AD has the highest non-fatal health burden. 3,4 AD is associated with sick leave, change or loss of job, and receiving disability pensions. 5 Data from the TREATgermany registry

show abstract

TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries

Cited by 29 publications

References 26 publications

A Standardised Core Outcome Set for Measurement and Reporting Sedentary Behaviour Interventional Research: The CROSBI Consensus Study

A Standardised Core Outcome Set for Measurement and Reporting Sedentary Behaviour Interventional Research: The CROSBI Consensus Study

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab

Contact Info

Product

Resources

About